574 related articles for article (PubMed ID: 18379962)
1. RNAi-based drug discovery and its application to therapeutics.
Hokaiwado N; Takeshita F; Banas A; Ochiya T
IDrugs; 2008 Apr; 11(4):274-8. PubMed ID: 18379962
[TBL] [Abstract][Full Text] [Related]
2. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
DeVincenzo JP
Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
[TBL] [Abstract][Full Text] [Related]
3. Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs.
Li T; Wu M; Zhu YY; Chen J; Chen L
Nucleic Acid Ther; 2014 Aug; 24(4):302-12. PubMed ID: 24796432
[TBL] [Abstract][Full Text] [Related]
4. [Application of atelocollagen-mediated siRNA delivery for RNAi therapies].
Honma K; Takeshita F; Ochiya T
Yakugaku Zasshi; 2007 May; 127(5):807-12. PubMed ID: 17473522
[TBL] [Abstract][Full Text] [Related]
5. RNA interference as a gene-specific approach for molecular medicine.
Grünweller A; Hartmann RK
Curr Med Chem; 2005; 12(26):3143-61. PubMed ID: 16375707
[TBL] [Abstract][Full Text] [Related]
6. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
7. The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.
Titze-de-Almeida R; David C; Titze-de-Almeida SS
Pharm Res; 2017 Jul; 34(7):1339-1363. PubMed ID: 28389707
[TBL] [Abstract][Full Text] [Related]
8. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
9. siRNA therapeutics: a clinical reality.
Saw PE; Song EW
Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
[TBL] [Abstract][Full Text] [Related]
10. Short interfering RNA (siRNA): tool or therapeutic?
Cejka D; Losert D; Wacheck V
Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
[TBL] [Abstract][Full Text] [Related]
11. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
Aigner A
Appl Microbiol Biotechnol; 2007 Aug; 76(1):9-21. PubMed ID: 17457539
[TBL] [Abstract][Full Text] [Related]
12. RNAi therapeutics: an update on delivery.
Nguyen T; Menocal EM; Harborth J; Fruehauf JH
Curr Opin Mol Ther; 2008 Apr; 10(2):158-67. PubMed ID: 18386228
[TBL] [Abstract][Full Text] [Related]
13. Commercial potential of RNAi.
Jain KK
Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033
[TBL] [Abstract][Full Text] [Related]
14. Future prospect of RNA interference for cancer therapies.
Ashihara E; Kawata E; Maekawa T
Curr Drug Targets; 2010 Mar; 11(3):345-60. PubMed ID: 20210759
[TBL] [Abstract][Full Text] [Related]
15. RNA interference strategies as therapy for respiratory viral infections.
DeVincenzo JP
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S118-22. PubMed ID: 18820571
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of chemically modified siRNA: Recent trends.
Selvam C; Mutisya D; Prakash S; Ranganna K; Thilagavathi R
Chem Biol Drug Des; 2017 Nov; 90(5):665-678. PubMed ID: 28378934
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic face of RNAi: in vivo challenges.
Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
[TBL] [Abstract][Full Text] [Related]
18. Gene silencing by chemically modified siRNAs.
Engels JW
N Biotechnol; 2013 Mar; 30(3):302-7. PubMed ID: 22820489
[TBL] [Abstract][Full Text] [Related]
19. RNA interference and cancer therapy.
Wang Z; Rao DD; Senzer N; Nemunaitis J
Pharm Res; 2011 Dec; 28(12):2983-95. PubMed ID: 22009588
[TBL] [Abstract][Full Text] [Related]
20. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
